FDA 483 - Aurobindo Pharma USA Inc - May 15, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Aurobindo Pharma USA Inc. in East Windsor, NJ, received a Form 483 following an inspection that identified significant deficiencies in its Drug Supply Chain Security Act (DSCSA) compliance systems. The firm failed to establish adequate procedures for identifying, investigating, and notifying authorities about suspect or illegitimate drug products. Additionally, the company did not report a cargo theft involving prescription drugs to the FDA within the required 24-hour timeframe.
ID · 51f91a8f-0ef6-4350-95ac-a9a7c46f8d32